Effects of omeprazole on symptoms and quality of life in Japanese patients with reflux esophagitis: final results of OMAREE, a large-scale clinical experience investigation

Shigeru Yoshida, Masahiro Nii, Masataka Date, Shigeru Yoshida, Masahiro Nii, Masataka Date

Abstract

Background: For patients with reflux esophagitis (RE), endoscopic findings alone (without the frequency and severity of symptoms) may not fully reflect the associated impact on health-related quality of life (QOL). There is not enough data about symptoms and QOL of Japanese patients with RE. The present study therefore investigated the epidemiological characteristics of such patients, and evaluated the efficacy and safety of omeprazole (and other gastrointestinal drugs, except proton pump inhibitors [PPIs]) in terms of improving patients' symptoms and QOL.

Methods: In a large-scale, specific clinical experience investigation of Japanese patients with RE, epidemiological characteristics, QOL and symptoms of the disease in relation to treatment with omeprazole and other gastrointestinal drugs, except PPIs, and safety data of omeprazole were collected. The Quality Of Life in Reflux and Dyspepsia questionnaire (QOLRAD) was used for QOL assessment.

Results: 9967 patients were included in the analysis (omeprazole: 7888). At baseline, 75.2% of patients had three or more upper gastrointestinal symptoms, and 31.5% of patients had six or more upper gastrointestinal symptoms. The overall mean QOLRAD score at baseline was 5.14 (the best score is 7). In the omeprazole group, the rate of satisfactory improvement in subjective symptoms was 61.7% and 81.8% at Weeks 4 and 8, respectively, and these were both significantly higher than those of patients treated with other drugs. In both the omeprazole group and the other drugs group, the QOLRAD score at Week 4 improved significantly from baseline, and the degree of improvement was significantly greater in the omeprazole group than in the other drugs group. The favourable tolerability profile of omeprazole was confirmed.

Conclusion: In a large-scale survey, omeprazole improved symptoms and QOL more effectively in Japanese patients with RE than other investigated drugs, and had a good tolerability profile.

Trial registration: ClinicalTrials.gov identifier: NCT00859287.

Figures

Figure 1
Figure 1
Profile and intensity of patient-reported symptoms at baseline (N = 8985).
Figure 2
Figure 2
Mean (± SD) QOLRAD-J domain and total scores at baseline.
Figure 3
Figure 3
Mean (± SD) QOLRAD-J domain and total scores according to the intensity of physician-reported symptoms at baseline.
Figure 4
Figure 4
Mean QOLRAD-J domain and total scores by frequency of symptoms at baseline.
Figure 5
Figure 5
Mean QOLRAD-J domain and total scores according to the number of patient-reported symptoms at baseline.
Figure 6
Figure 6
Mean QOLRAD-J item scores at baseline.
Figure 7
Figure 7
Mean (± SD) QOLRAD-J domain and total scores at baseline, and at Weeks 4 and 8.
Figure 8
Figure 8
Mean (± SD) change in QOLRAD-J domain and total scores from baseline to Weeks 4 and 8.

References

    1. Green JRB. Is there such an entity as mild oesophagitis? Eur J Clin Res. 1993;4:29–34.
    1. Glise H, Hallerback B, Wiklund I. Quality of life: a reflection of symptoms and concerns. Scand J Gastroenterol. 1996;221:14–17. doi: 10.3109/00365529609095545.
    1. Yamagishi H, Koike T, Ohara S, Abe Y, Iijima K, Imatani A. et al.Clinical characteristics of gastroesophageal reflux disease in Japan. Hepatogastroenterology. 2009;56:1032–103.
    1. Danjo A, Yamaguchi K, Fujimoto K, Saitoh T, Inamori M, Ando T. et al.Comparison of endoscopic findings with symptom assessment systems (FSSG and QUEST) for gastroesophageal reflux disease in Japanese centres. J Gastroenterol Hepatol. 2009;24:633–638. doi: 10.1111/j.1440-1746.2008.05747.x.
    1. Ware J, Sherbourne C. The MOS 36-item short-form health survey (SF-36) I. Conceptual framework and item selection. Med Care. 1992;30:473–483. doi: 10.1097/00005650-199206000-00002.
    1. Dupuy H. Assessment of Quality of Life in Clinical Trials of Cardiovascular Therapies, Chapter 9 The psychological general well-being (PGWB) index. Le Jacq Pub. 1984. pp. 170–183.
    1. Dimenas E, Glise H, Hallerback B, Hernqvist H, Svedlund J, Wiklund I. Well-being and gastrointestinal symptoms among patients referred to endoscopy owing to suspected duodenal ulcer. Scand J Gastroenterol. 1995;30:1046–1052. doi: 10.3109/00365529509101605.
    1. Wiklund IK, Junghard O, Grace E, Talley NJ, Kamm M, Veldhuyzen van Zanten S, Paré P, Chiba N, Leddin DS, Bigard M-A. et al.Quality of life in reflux and dyspepsia patients. Psychometric documentation of a new disease-specific questionnaire (QOLRAD) Eur J Surg. 1998;583(Suppl):41–49.
    1. Hongo M, Kinoshita Y, Shimozuma K, Kumagai Y, Sawada M, Nii M. Psychometric validation of the Japanese translation of the Quality of Life in Reflux and Dyspepsia questionnaire in patients with heartburn. J Gastroenterol. 2007;42:807–815. doi: 10.1007/s00535-007-2098-9.
    1. Dimenas E. Methodological aspects of evaluation of quality of life in upper gastrointestinal diseases. Scand J Gastroenterol. 1993;199:18–21. doi: 10.3109/00365529309098350.
    1. Wiklund I. Quality of life in patients with gastroesophageal reflux disease. Am J Gastroenterol. 2001;96(Suppl 8):S46–S53. doi: 10.1016/S0002-9270(01)02591-6.
    1. McDougall NI, Johnston BT, Kee F, Collins JS, McFarland RJ, Love AH. Natural history of reflux oesophagitis: a 10 year follow up of its effect on patient symptomatology and quality of life. Gut. 1996;38:481–486. doi: 10.1136/gut.38.4.481.
    1. Talley NJ, Fullerton S, Junghard O, Wiklund I. Quality of life in patients with endoscopy-negative heartburn: reliability and sensitivity of disease-specific instruments. Am J Gastroenterol. 2001;96:1998–2004. doi: 10.1111/j.1572-0241.2001.03932.x.
    1. Adachi K, Matsumori Y, Fujisawa T, Kamada T, Kusaka M, Ohumi T, Iwakiri R, Yamaguchi K, Danjo A, Hori K. et al.Symptom diversity of patients with reflux esophagitis: effect of omeprazole treatment. J Clin Biochem Nutr. 2006;39:46–54. doi: 10.3164/jcbn.39.46.
    1. Veldhuyzen van Zanten SJ, Chiba N, Armstrong D, Barkun A, Thomson A, Smyth S, Escobedo S, Lee J, Sinclair P. A randomized trial comparing omeprazole, ranitidine, cisapride, or placebo in Helicobacter pylori negative, primary care patients with dyspepsia: the CADET-HN Study. Am J Gastroenterol. 2005;100:1477–1488. doi: 10.1111/j.1572-0241.2005.40280.x.
    1. Miwa H, Sakurai K, Akiyama J, Mabe K. Round table discussion: current status and countermeasure for dyspeptic symptoms in Japanese. J Med Pharm Sci. 2008;60:427–436.
    1. Havelund T, Lind T, Wiklund I, Glise H, Hernqvist H, Lauritsen K, Lundell L, Pedersen SA, Carlsson R, Junghard O, Stubberöd A, Anker-Hansen O. Quality of life in patients with heartburn but without esophagitis: effects of treatment with omeprazole. Am J Gastroenterol. 1999;94(7):1782–1789. doi: 10.1111/j.1572-0241.1999.01206.x.

Source: PubMed

Sponsors and Collaborators

Medical Conditions

Drug Interventions

3
Subscribe